Overview
Tumor neoantigen burden outperforms tumor mutational burden (TMB) in prediction of patient response to immune checkpoint blockade (ICB) therapy by better capturing the biological mechanism underlying response [1]. However, immune recognition of neoantigens by T-cells requires more than antigen presentation, which has been the focus of tumor neoantigen burden thus far. To address this need, we extend the existing SHERPA™ MHC-presentation framework [2] to predict neoantigen immunogenicity.
